NEW YORK, April 14, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Celgene Corporation (NASDAQ: CELG), Vanda Pharmaceuticals, Inc.
(NASDAQ: VNDA), Chelsea Therapeutics International Ltd. (NASDAQ:
CHTP), Neurocrine Biosciences Inc. (NASDAQ: NBIX), and USANA Health
Sciences Inc. (NYSE: USNA). Private wealth members receive these
notes ahead of publication. To reserve complementary membership,
limited openings are available at:
http://www.analystsreview.com/1050-100free
Celgene Corporation Analyst Notes
On April 1, 2014, Celgene
Corporation (Celgene) announced that it will host a conference call
on April 24, 2014, at 9:00 a.m. ET, to discuss its Q1 2014 financial
and operational results. The Company informed that interested
parties can access a live webcast of the call via the Investor
Relations page in Celgene's website. In other news dated
March 24, 2014, Celgene announced
that the U.S. Food and Drug Administration (FDA) has approved
OTEZLA® (apremilast), its oral, selective inhibitor of
phosphodiesterase 4 (PDE4) the treatment of adult patients with
active psoriatic arthritis. According to the Company, OTEZLA® is
the only FDA-approved oral treatment for psoriatic arthritis. The
full analyst notes on Celgene Corporation are available to download
free of charge at:
http://www.analystsreview.com/1050-CELG-14Apr2014.pdf
Vanda Pharmaceuticals, Inc. Analyst Notes
On April 9, 2014, Vanda
Pharmaceuticals, Inc. (Vanda) announced the availability of
HETLIOZ™. According to the Company, HETLIOZ™ is the first treatment
approved by the U.S. Food and Drug Administration (FDA) for
Non-24-Hour Sleep-Wake Disorder (Non-24). The Company stated that
it has launched HETLIOZSolutions™ to support and facilitate
the treatment of totally blind people living with Non-24. The
Company added that the HETLIOZSolutions™ will provide patients with
a host of resources including information about Non-24 and
HETLIOZ™, insurance support, overview of financial assistance
programs, and pharmacy access. Mihael H.
Polymeropoulos, M.D., Vanda's President and CEO, stated,
"The availability of HETLIOZ marks a major milestone for totally
blind people who have been without an approved, safe and effective
treatment for Non-24. We are also excited to bring a broad range of
services to patients through HETLIOZSolutions." The full analyst
notes on Vanda Pharmaceuticals, Inc. are available to download free
of charge at:
http://www.analystsreview.com/1050-VNDA-14Apr2014.pdf
Chelsea Therapeutics International Ltd. Analyst
Notes
On April 9, 2014, Chelsea
Therapeutics International Ltd.'s stock went up by 3.94% to end the
trading session at $5.54. Over the
past six-month period, the Company's stock increased a 108.27%,
compared to the Nasdaq Composite Index which went up by 13.76%
during the same period. The full analyst notes on Chelsea
Therapeutics International Ltd. are available to download free of
charge at:
http://www.analystsreview.com/1050-CHTP-14Apr2014.pdf
Neurocrine Biosciences Inc. Analyst Notes
On April 9, 2014, Neurocrine
Biosciences Inc.'s stock went up by 3.34%, closing the day at
$14.53. In the past three trading
days, the Company's stock went up by 1.68%, compared to the Nasdaq
Composite which reflected an increase of 1.36% during the same
period. The full analyst notes on Neurocrine Biosciences Inc. are
available to download free of charge at:
http://www.analystsreview.com/1050-NBIX-14Apr2014.pdf
USANA Health Sciences Inc. Analyst Notes
On April 7, 2014, USANA Health
Sciences Inc. (USANA) announced that three thousand people have
shed more than 16,000 pounds in just three months under its RESET
Challenge: Destination Transformation in an effort to support
people from all walks of life in their weight loss efforts and
overall well-being. According to USANA, more than $300,000 in prizes will be awarded to 23 grand
prize winners of the RESET Challenge, including a shopping spree,
makeover, and photoshoot. Doug
Braun, USANA Chief Marketing Officer, stated, "The
incredible results achieved from last year's challenge were more
than we ever anticipated. We were excited to once again help
thousands of individuals get healthy, maintain their health, and
lose weight this year." The full analyst notes on USANA Health
Sciences Inc. are available to download free of charge at:
http://www.analystsreview.com/1050-USNA-14Apr2014.pdf
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
http://www.analystsreview.com/
SOURCE Analysts Review